299 papers found
Refreshing results…
Superiority of IFN Versus HU Using a Novel Biomarker-Based Tool for Assessment of Disease Burden in MPNs
Significantly Upregulated Thrombo-Inflammatory Genes Are Normoregulated or Significantly Downregulated during Treatment with Interferon-Alpha2 in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
Vascular Diseases In Patients With Chronic Myeloproliferative Neoplasms – Impact Of Comorbidity
Methylation age as a correlate for allele burden, disease status, and clinical response in myeloproliferative neoplasm patients treated with vorinostat
Time for revival of the red blood cell count and red cell mass in the differential diagnosis between essential thrombocythemia and polycythemia vera?
Association of the blood eosinophil count with end-organ symptoms
B‐cell frequencies and immunoregulatory phenotypes in myeloproliferative neoplasms: Influence of ruxolitinib, interferon‐α2, or combination treatment
Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population
Abstract 4911: Collaboration on quality of life in myeloproliferative neoplasms: Analysis of body mass index and symptom burden
Progression of JAK2-mutant polycythemia vera to CALR-mutant myelofibrosis severely impacts on disease phenotype and response to therapy
Variant‐specific discrepancy when quantitatingBCR‐ABL1e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay
Smoking and Increased White and Red Blood Cells
Neo-antigen specific memory T-cell responses in healthy individuals
Bridging blood cancers and inflammation: The reduced Cancitis model
Ruxolitinib treatment reduces monocytic superoxide radical formation without affecting hydrogen peroxide formation or systemic oxidative nucleoside damage in myelofibrosis
Statin treatment, oxidative stress and inflammation in a Danish population
High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals
Inflammatory functional iron deficiency common in myelofibrosis, contributes to anaemia and impairs quality of life. From the Nordic MPN study Group
Ropeginterferon Alfa-2b versus Standard Therapy for Polycythaemia Vera; a Randomised, Controlled, Phase III Trial
Anxiety and depression in patients with Philadelphia-negative myeloproliferative neoplasms: a nationwide population-based survey in Denmark
Missing publications? Read more about our data sources.